XML 65 R56.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Subsequent events (Details) € / shares in Units, € in Thousands |  | 6 Months Ended |
--- | --- | --- | ---
Jul. 01, 2022 € / shares | Jun. 30, 2022 EUR (€) USD ($) | Jun. 08, 2022 EUR (€) USD ($) € / shares
Disclosure of detailed information about business combination [line items] |  |  |
Shares transferred | $ |  | 810,242 |
Net amount of discharging contractual obligations |  |  | € 660
Closing date share price | € / shares | € 13.64 |  |
Percent of first milestone payment |  | 50.00% |
Cash acquired |  | € 308 |
Transactions costs related to acquisition |  | € 400 |
Average share price | € / shares |  |  | € 16.44
Milestones |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Percent of first milestone payment |  | 50.00% |
Minimum |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Cash payments |  | € 250 |
Minimum | Milestones |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Shares transferred | $ |  | 194.647 |
Percent of second milestone payment |  | 10.00% |
Maximum |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Cash payments |  | € 660 |
Maximum | Milestones |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Shares transferred | $ |  | 778.588 |
Percent of second milestone payment |  | 40.00% |
Frame Pharmaceuticals |  |  |
Disclosure of detailed information about business combination [line items] |  |  |
Total purchase price |  |  | € 32,000
Shares transferred | $ |  |  | 1,783,460

X
- Definition Percent of first milestone payment. + References No definition available. + Details
Name: | cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling
Namespace Prefix: | cvac_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percent of second milestone payment. + References No definition available. + Details
Name: | cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans
Namespace Prefix: | cvac_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the closing date share price. + References No definition available. + Details
Name: | cvac_PurchasePriceAllocationSharePriceAsOfClosingDate
Namespace Prefix: | cvac_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph f -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph m -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph f -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_CashTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph f -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_LiabilitiesIncurred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B64 -Subparagraph f -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2021-01-01 -Paragraph 45 -Subparagraph b -Clause vi -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_MilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |